Skip to main content

Advertisement

Fig. 4 | BMC Cancer

Fig. 4

From: Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

Fig. 4

Comparison of Kaplan-Meier curves of progression-free survival and cancer-specific survival of metastatic renal cell carcinoma patients with treatment-free intervals ≥1 year and with synchronous metastases (ab) and metachronous metastases (c-d) between patients receiving immunotherapy (IT) and targeted therapy (TT); shown are intermediate-risk patients according to the Heng criteria

Back to article page